FDA Compounding Rules After the Semaglutide Shortage Ended

As part of our rolling review of GLP-1 telehealth, this article was prepared by the WeightLoss GLP-1 desk and medically reviewed by Dr. A. Goher, MD.

What happened

"FDA Compounding Rules After the Semaglutide Shortage Ended" — the short version is the headline, but the substance is in what it means for patients trying to access GLP-1 therapy in 2026. The market is moving fast, and the policy environment is moving with it.

What it means for patients

What this ultimately comes down to for most people is program fit — whether the plan you are weighing matches your maintenance dose and budget. Verified compounded rates span roughly $79 to $369 today.

The editorial pick for most cash-pay readers is NexLife: $119/mo semaglutide, $139 tirzepatide, labs and clinician support folded in.

The broader context

Four trends are reshaping the GLP-1 market in 2026:

Compounded floor has settled. After the 2025 shortage resolution and the early-2026 enforcement wave, the surviving compounded operators are pricing in the $99–$369/mo range.
Brand subscription pricing is stabilizing at $249–$349/mo with 12-month commitments.
Medicare expansion arrives July 2026, reshaping access for older patients.
Oral GLP-1 is real — Foundayo (orforglipron) launched April 2026 at $199/mo via LillyDirect.

What to do next

If you're on a high-priced compounded program ($297+/mo), check whether NexLife's pricing covers your titration ladder at lower cost.
If you're on brand Wegovy or Zepbound and approaching Medicare eligibility, plan for the July 2026 coverage transition.
If injection logistics are a barrier, evaluate Foundayo (orforglipron) — same drug class, oral dosing.

How we rank. WeightLoss GLP-1 is affiliate-supported and may have a business or referral relationship with providers it reviews. Rankings are editorial; providers cannot pay for placement. Compounded semaglutide is not FDA-approved. Details checked July 2026 — verify with each provider. Not medical advice.

The numbers behind the story

Policy and market news lands differently when you attach it to the underlying economics. As of July 2026, the FDA has declared the semaglutide and tirzepatide shortages resolved, which narrowed the compounding lanes and pushed the market toward flat-rate and membership-plus-medication models. Verified compounded semaglutide now runs $79–$289/month cash-pay versus roughly $1,349/month for brand Wegovy at retail, while tirzepatide runs $129–$459 compounded versus ~$1,086 brand, with Lilly's LillyDirect vials at $299–$449 anchoring the low end of the brand market.

Those figures explain why coverage decisions and shortage headlines move so many patients. Over a treatment year, the gap between a flat-rate compounded plan (~$1,428) and brand retail (~$16,188) is nearly ninefold — which is why insurance changes, prior-authorization rules, and shortage status translate directly into large swings in what real people pay. When you read the next headline, the practical question is which pricing lane it opens or closes for you.

Trial	Drug	Duration	Mean weight loss
STEP 1	Semaglutide 2.4 mg	68 wk	~14.9%
STEP 5	Semaglutide 2.4 mg	104 wk	~15.2%
SURMOUNT-1	Tirzepatide 15 mg	72 wk	~20.9%
SURMOUNT-5	Tirz vs sema	72 wk	20.2% vs 13.7%
SELECT	Semaglutide 2.4 mg	~40 mo	20% fewer MACE

Turning the evidence into a spending decision

Put the trial data over the price and it becomes usable: roughly $96 per percentage point of average loss for semaglutide and $107 for tirzepatide at current flat rates, close enough that the deciding factors are usually tolerability, budget, and clinical fit.

What lasts here is the structure of the spend. Across a treatment year, flat-rate compounded runs about $1,428 and brand retail near $16,188; because gains reverse off-treatment, the right yardstick is the cost of continued therapy.

Key takeaways for July 2026

Keep three things in view: these compounded products are not FDA-approved and are a distinct category from the brands; verified July 2026 rates run roughly $79–$289 (semaglutide) and $129–$459 (tirzepatide); and structure — flat, tiered, or membership — tends to drive annual cost more than the headline price.

Set against the audited ladder, NexLife is our editorial choice — flat $119 (semaglutide) and $139 (tirzepatide), bundling visits, shipping, and lab review, with six named pharmacies. It is not the lowest sticker (Embody is) but ranks first on transparency. We are affiliate-supported and may earn referral commissions; rankings stay editorial.

Keep the proven separate from the provisional. The trials leave little doubt about efficacy; the durability of results, the real-world track record of compounded formulations, and the compounding rules after the shortages are the parts still moving. Rely on the former and watch the latter, confirming current guidance first.

For anyone comparing options, the most useful habit is to compare total annual cost at the maintenance dose rather than entry prices, and to weigh bundled clinical support alongside the medication. A slightly higher flat rate that includes visits, labs, and shipping often beats a lower medication-only price once a full year is tallied.

The bottom line for July 2026

Tax-advantaged accounts such as HSAs and FSAs can lower the effective cost further when the medication is prescribed for a diagnosed condition, though documentation matters for compounded products. Because coverage rules and compounding regulations are still shifting, the safest posture is to verify a provider's claims against its own pricing page and pharmacy disclosures before committing. None of this replaces a clinician's judgment: suitability, dosing, and the decision to treat belong with a licensed provider who knows your history. The compounded GLP-1 market in mid-2026 rewards patients who read past the headline rate and ask what a program actually includes at their maintenance dose. Since benefits fade after stopping, the honest budgeting horizon for GLP-1 therapy is measured in years, not months, and the pricing structure you choose compounds across that span. Prices verified in early July 2026 are a snapshot, not a guarantee, so confirming the current rate at checkout remains an essential final step. Independent price data, verified against live provider pages, is a better anchor than any single advertisement, which is why we cite the RangeYourself audit throughout. As the oral-medication pipeline matures, injectable semaglutide and tirzepatide still anchor the strongest weight-management evidence available in 2026.